Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
about
FDG PET-CT: Need for Vigilance in Patients Treated with Bleomycin.Non-infectious pulmonary toxicity of rituximab: a systematic review.The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity.Role of (18)F-FDG PET-CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer - 2 Case Reports.[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma.
P2860
Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
@en
Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
@nl
type
label
Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
@en
Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
@nl
prefLabel
Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
@en
Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
@nl
P2093
P1476
Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
@en
P2093
Homer A Macapinlac
Silvana C Faria
Toshiki Kazama
Yoshitaka Uchida
P2860
P2888
P304
P356
10.1007/S12149-007-0089-9
P577
2008-02-01T00:00:00Z